PT  - JOURNAL ARTICLE
AU  - Xu, Jie
AU  - Cheng, Yajiao
AU  - Yuan, Xiaoling
AU  - Li, Wei V.
AU  - Zhang, Lanjing
TI  - Trends and prediction in daily incidence of novel coronavirus infection in China, Hubei Province and Wuhan City: an application of Farr’s law
AID  - 10.1101/2020.02.19.20025148
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.19.20025148
4099  - http://medrxiv.org/content/early/2020/02/23/2020.02.19.20025148.short
4100  - http://medrxiv.org/content/early/2020/02/23/2020.02.19.20025148.full
AB  - Background The recent outbreak of novel coronavirus (2019-nCoV) has infected tens of thousands of patients in China. Studies have forecasted future trends of the incidence of 2019-nCoV infection, but appeared unsuccessful. Farr’s law is a classic epidemiology theory/practice for predicting epidemics. Therefore, we used and validated a model based on Farr’s law to predict the daily-incidence of 2019-nCoV infection in China and 2 regions of high-incidence.Methods We extracted the 2019-nCoV incidence data of China, Hubei Province and Wuhan City from websites of the Chinese and Hubei health commissions. A model based on Farr’s law was developed using the data available on Feb. 8, 2020, and used to predict daily-incidence of 2019-nCoV infection in China, Hubei Province and Wuhan City afterward.Results We observed 50,995 (37001 on or before Feb. 8) incident cases in China from January 16 to February 15, 2020. The daily-incidence has peaked in China, Hubei Providence and Wuhan City, but with different downward slopes. If no major changes occur, our model shows that the daily-incidence of 2019-nCoV will drop to single-digit by February 25 for China and Hubei Province, but by March 8 for Wuhan city. However, predicted 75% confidence intervals of daily-incidence in all 3 regions of interest had an upward trend. The predicted trends overall match the prospectively-collected data, confirming usefulness of these models.Conclusions This study shows the daily-incidence of 2019-nCoV in China, Hubei Province and Wuhan City has reached the peak and was decreasing. However, there is a possibility of upward trend.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and their updates are available at https://github.com/thezhanglab/coronavirus https://github.com/thezhanglab/coronavirus